Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Patent
1997-12-30
1999-08-10
Shah, Mukund J.
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
536 2644, C07D48722
Patent
active
059360828
ABSTRACT:
A purified complex of a metallocorrinoid, such as a vitamin B.sub.12 compound, and a pharmacological agent, such as nitric oxide, that is capable of site-specific delivery of the pharmacological agent in vivo. The pharmacological agent is bound to the metallocorrinoid in a non-donating solvent. The complex is then resuspended in a biocompatible medium and inserted into the recipient. The pharmacological agent then releases in vivo, especially under acidic conditions.
REFERENCES:
Kaczka et al., Vitamin B.sub.12.XVI. Modification of Cyano-Cobalamin, Biophys. Acta, vol. 73 (1940), pp. 3569-3572.
Ryel et al., Uptake and Subcellular Distribution of Vitamin B.sub.12 in Mouse L1210 Leukemic Lymphoblasts, Blood, vol. 44, No. 3 (1974), pp. 427-433.
LaVan et al., Oxygen and Wound Healing, Clinics in Plastic Surgery, vol. 17, No. 3 (1990), pp. 463-472.
Scott, How Nature Synthesizes Vitamin B.sub.12 --A Survey of the Last Four Billion Years, Angewandte Chemie, vol. 32, No. 9 (1993), pp. 1223-1376.
Li et al., Effects of Hydroxocobalamin and Haemoglobin on No-Mediated Relaxations in the Rat Anoccocygeus Muscle, Clinical and Experimental Pharmacology and Physiology, vol. 20 (1993), pp. 633-640.
Rajanayagam et al., Differential Effects of Hydroxocobalamin on NO-Mediated Relaxations in Rat Aorta and Anococcygeus Muscle, J. Pharmacol. vol. 108 (1993), pp. 3-5.
King et al., Cobalt: B.sub.12 Enzymes & Coenzymes, Encyclopedia Inorganic Chemistry, vol. 2 (1994), pp. 697-712.
Greenberg et al., Hydroxocobalamin Vitamin B.sub.12a Prevents and Reverses Endotoxin-Induced Hypotension and Mortality in Rodents: Role of Nitric Oxide, The Journal of Pharmacology and Experimental Therapeutics, vol. 273, No. 1 (1995), pp. 257-265.
Sagar et al., Nitric Oxide and Anti-Cancer Therapy, Cancer Treatment Reviews, vol. 21 (1995), pp. 159-181.
Quadros et al., The Dynamics of Cobalamin Utilization in L-1210 Mouse Leukemia Cells: A Model of Cellular Cobalamin Metabolism, Biochimica et Biophysica Acta 1244 (1995), pp. 395-403.
Rochelle et al., Interactions Between Hydroxocobalamin and Nitric Oxide (NO): Evidence for a Redox Reaction Between NO and Reduced Cobalamin and Reversible NO Binding to Oxidized Cobalamin, The Journal of Pharmacology and Experimental Therapeutics, vol. 245, No. 1 (1995), pp. 48-52.
Shabani et al., Enhancement of Wound Repair with a Topically Applied Nitric Oxide-Releasing Polymer, Wound Repair and Regeneration, vol. 4, No. 3 (1996), pp. 353-362.
Brouwer et al., Nitric Oxide Interactions with Cobalamins: Biochemical and Functional Consequences, vol. 88, No. 5 (1996), pp. 1857-1864.
Russell-Jones., Chem. Abst. 1990: 42564.
Shah Mukund J.
Sripada Pavanaram K.
The University of Akron
LandOfFree
Metallocorrinoids as biologically compatible carriers of pharmac does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Metallocorrinoids as biologically compatible carriers of pharmac, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Metallocorrinoids as biologically compatible carriers of pharmac will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1121281